Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 1/20 | 0.62 |
| ▸ | MGLL | Q99685 | 9/20 | 0.61 |
| ▸ | FAAH | O00519 | 5/20 | 0.58 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514697 | 0.90 | MGLL (0.59) | PPARDPPARAMGLLFAAHDDAH1 | |
| Hydrochloric Acid SCHEMBL28737900 | 0.88 | MGLL (0.58) | PPARDPPARAMGLLFAAHDDAH1 | |
| Hydrazine SCHEMBL27822007 | 0.87 | MGLL (0.56) | PPARDPPARAMGLLFAAHDDAH1 | |
| SCHEMBL4388793 | 0.82 | MGLL (0.77) | MGLLFAAHDDAH1HSP90AA1PKM | |
| SCHEMBL6755043 | 0.81 | MGLL (0.62) | MGLLFAAHDDAH1HSP90AA1PKM | |
| Hydrochloric Acid SCHEMBL6753371 | 0.80 | MGLL (0.60) | MGLLFAAHDDAH1HSP90AA1PKM | |
| SCHEMBL8510655 | 0.80 | MGLL (0.49) | PPARDPPARAMGLLFAAHDDAH1 | |
| Succinimide SCHEMBL132748 | 0.80 | MGLL (0.49) | PPARDPPARAMGLLFAAHDDAH1 | |
| SCHEMBL9751413 | 0.79 | MGLL (0.67) | MGLLFAAHDDAH1HSP90AA1PKM | |
| SCHEMBL741572 | 0.79 | MGLL (0.59) | PPARDPPARAMGLLFAAHDDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373824-A1 | IMMUNOCONJUGATES AND METHODS | Zeno Management, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117715913-A | Immunoconjugates and methods | 芝诺管理公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11806405-B1 | Immunoconjugates and methods | ZENO MANAGEMENT, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023004266-A1 | IMMUNOCONJUGATES AND METHODS | RECURIUM IP HOLDINGS, LLC (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-2256133-B1 | Bioconjugation of macromolecules | SIGMA ALDRICH CO LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2319854-B1 | Bioconjugation Of Macromolecules | SIGMA ALDRICH CO LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9045552-B2 | Non-viral delivery of compounds to mitochondria | WAKE FOREST UNIVERSITY (US) | 2015-06-02 | — | — | US | disclosed |
| US-8735341-B2 | Non-viral delivery of compounds to mitochondria | WAKE FOREST UNIVERSITY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8283444-B2 | biodrug fusion protein comprising active mitochondrial protein or peptide, a mitochondrial membrane-permeant peptide and linking to a mitochondrial targeting sequence; targeting sequence is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm; mitochondrial disorders | WAKE FOREST UNIVERSITY (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110245146-A1 | Non-Viral Delivery of Compounds to Mitochondria | PAYNE R MARK | 2011-10-06 | — | — | US | disclosed |
| US-20050169904-A1 | Non-viral delivery of compounds to mitochondria | WAKE FOREST UNIVERSITY | 2005-08-04 | — | — | US | disclosed |
| WO-2005042560-A2 | NON-VIRAL DELIVERY OF COMPOUNDS TO MITOCHONDRIA | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2005-05-12 | — | — | WO | disclosed |
| US-6737236-B1 | DERIVATIZING OLIGONUCLEOTIDES AND PROTEINS USING CYCLOADDITION REACTIONS INCLUDING DIELS-ALDER REACTION OR 1,3-DIPOLAR CYCLOADDITION REACTIONS | PROLIGO, LLC | 2004-05-18 | — | — | US | disclosed |
| US-20030215801-A1 | Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method | SIGMA-ALDRICH CO., LLC | 2003-11-20 | — | — | US | disclosed |
| EP-1287404-A4 | METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGATION METHOD | PROLIGO LLC (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1287404-A1 | METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGATION METHOD | Proligo LLC (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001084234-A1 | METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGATION METHOD | PROLIGO LLC (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-0968223-A1 | BIOCONJUGATION OF MACROMOLECULES | Proligo L.L.C. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998030575-A1 | BIOCONJUGATION OF MACROMOLECULES | PROLIGO LLC (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0001997-B1 | ELECTRON BEAM-CURABLE PHOTORESIST LACQUERS | BAYER AG (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806405-B1 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | PPARD 3528/4885PPARA 3771/4885MGLL 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.